Concepedia

Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.

M Usman, Naveen Naz Syed, Ghulam Nabi Kakepoto, Salman Naseem Adil, M Khurshid

PubMed · 2007 · 26 citations · 19 references

Abstract

Imatinib mesylate has substantial activity in chronic phase of CML. Low Sokal score at time of presentation predict the higher hematologic as well as cytogenetic response in patients with chronic phase.

References

19

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Stephen G. O’Brien, François Guilhot, Richard A. Larson et al. · New England Journal of Medicine · 2003 · 3.5K citations · Full text

Prognostic discrimination in "good-risk" chronic granulocytic leukemia

JE Sokal, Cox Eb, Michele Baccarani et al. · Blood · 1984 · 1K citations · Full text

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

Jörge E. Cortes, Moshe Talpaz, Francis J. Giles et al. · Blood · 2003 · 236 citations · Full text

Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center

Tanja Lahaye, Birte Riehm, Ute Berger et al. · Cancer · 2005 · 226 citations

Emergence of clonal cytogenetic abnormalities in Ph−cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

Thomas G.P. Bumm, Christel Müller, Haifa Kathrin Al‐Ali et al. · Blood · 2003 · 221 citations